In this podcast, we commemorate Bladder Cancer Awareness Month in May with a special limited series, where we invite a special guest to discuss and share their expert perspectives within this ever evolving field. This week, Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, will be talking about antibody-drug conjugates, which have made a big impact in the treatment landscape of bladder cancer and other solid tumors. He will provide his thoughts on the approval of enfortumab vedotin, managing toxicities, and the future of ADCs.